Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia

Martin Adiels, Marja Riitta Taskinen, Elias Björnson, Linda Andersson, Niina Matikainen, Sanni Söderlund, Juhani Kahri, Antti Hakkarainen, Nina Lundbom, Carina Sihlbom, Annika Thorsell, Haihong Zhou, Kirsi H. Pietiläinen, Chris Packard, Jan Borén*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

38 Citations (Scopus)


Aims: To investigate how apolipoprotein C-III (apoC-III) metabolism is altered in subjects with type 2 diabetes, whether the perturbed plasma triglyceride concentrations in this condition are determined primarily by the secretion rate or the removal rate of apoC-III, and whether improvement of glycaemic control using the glucagon-like peptide-1 analogue liraglutide for 16 weeks modifies apoC-III dynamics. Materials and Methods: Postprandial apoC-III kinetics were assessed after a bolus injection of [5,5,5- 2 H 3 ]leucine using ultrasensitive mass spectrometry techniques. We compared apoC-III kinetics in two situations: in subjects with type 2 diabetes before and after liraglutide therapy, and in type 2 diabetic subjects with matched body mass index (BMI) non-diabetic subjects. Liver fat content, subcutaneous abdominal and intra-abdominal fat were determined using proton magnetic resonance spectroscopy. Results: Improved glycaemic control by liraglutide therapy for 16 weeks significantly reduced apoC-III secretion rate (561 ± 198 vs. 652 ± 196 mg/d, P = 0.03) and apoC-III levels (10.0 ± 3.8 vs. 11.7 ± 4.3 mg/dL, P = 0.035) in subjects with type 2 diabetes. Change in apoC-III secretion rate was significantly associated with the improvement in indices of glucose control (r = 0.67; P = 0.009) and change in triglyceride area under the curve (r = 0.59; P = 0.025). In line with this, the apoC-III secretion rate was higher in subjects with type 2 diabetes compared with BMI-matched non-diabetic subjects (676 ± 208 vs. 505 ± 174 mg/d, P = 0.042). Conclusions: The results reveal that the secretion rate of apoC-III is associated with elevation of triglyceride-rich lipoproteins in subjects with type 2 diabetes, potentially through the influence of glucose homeostasis on the production of apoC-III.

Original languageEnglish
Pages (from-to)1861-1870
JournalDiabetes, Obesity and Metabolism
Issue number8
Early online date1 Jan 2019
Publication statusPublished - Aug 2019
MoE publication typeA1 Journal article-refereed


  • apolipoprotein C-III
  • kinetics
  • lipoproteins
  • stable isotopes
  • type 2 diabetes


Dive into the research topics of 'Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia'. Together they form a unique fingerprint.

Cite this